Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SHFS vs LGND vs BFIN vs PRGO vs NECB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SHFS
SHF Holdings, Inc.

Banks - Regional

Financial ServicesNASDAQ • US
Market Cap$1M
5Y Perf.-99.8%
LGND
Ligand Pharmaceuticals Incorporated

Biotechnology

HealthcareNASDAQ • US
Market Cap$4.35B
5Y Perf.+67.4%
BFIN
BankFinancial Corporation

Banks - Regional

Financial ServicesNASDAQ • US
Market Cap$150M
5Y Perf.+3.4%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.62B
5Y Perf.-71.4%
NECB
Northeast Community Bancorp, Inc.

Banks - Regional

Financial ServicesNASDAQ • US
Market Cap$338M
5Y Perf.+130.3%

SHFS vs LGND vs BFIN vs PRGO vs NECB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SHFS logoSHFS
LGND logoLGND
BFIN logoBFIN
PRGO logoPRGO
NECB logoNECB
IndustryBanks - RegionalBiotechnologyBanks - RegionalDrug Manufacturers - Specialty & GenericBanks - Regional
Market Cap$1M$4.35B$150M$1.62B$338M
Revenue (TTM)$18M$251M$74M$4.18B$157M
Net Income (TTM)$-53M$49M$2M$-1.82B$44M
Gross Margin104.7%85.9%66.2%34.2%66.1%
Operating Margin-24.2%7.0%6.8%-4.1%39.6%
Forward P/E24.6x15.2x5.5x7.8x
Total Debt$12M$7M$39M$3.97B$75M
Cash & Equiv.$2M$72M$119M$532M$81M

SHFS vs LGND vs BFIN vs PRGO vs NECBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SHFS
LGND
BFIN
PRGO
NECB
StockAug 21May 26Return
SHF Holdings, Inc. (SHFS)1000.2-99.8%
Ligand Pharmaceutic… (LGND)100167.4+67.4%
BankFinancial Corpo… (BFIN)100103.4+3.4%
Perrigo Company plc (PRGO)10028.6-71.4%
Northeast Community… (NECB)100230.3+130.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: SHFS vs LGND vs BFIN vs PRGO vs NECB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LGND leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. BFIN and NECB also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SHFS
SHF Holdings, Inc.
The Banking Pick

SHFS is the clearest fit if your priority is bank quality.

  • NIM 46.1% vs BFIN's 3.4%
Best for: bank quality
LGND
Ligand Pharmaceuticals Incorporated
The Growth Play

LGND carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 27.3%, EPS growth -107.5%, 3Y rev CAGR -11.6%
  • Lower volatility, beta 1.03, Low D/E 0.9%, current ratio 8.93x
  • 27.3% revenue growth vs SHFS's -9.2%
  • +116.0% vs SHFS's -80.2%
Best for: growth exposure and sleep-well-at-night
BFIN
BankFinancial Corporation
The Banking Pick

BFIN ranks third and is worth considering specifically for stability.

  • Beta 0.56 vs SHFS's 1.83
Best for: stability
PRGO
Perrigo Company plc
The Income Pick

PRGO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 10 yrs, beta 1.21, yield 9.8%
  • Beta 1.21, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.5x vs 15.2x)
  • 9.8% yield, 10-year raise streak, vs NECB's 4.0%, (2 stocks pay no dividend)
Best for: income & stability and defensive
NECB
Northeast Community Bancorp, Inc.
The Banking Pick

NECB is the clearest fit if your priority is long-term compounding.

  • 459.8% 10Y total return vs LGND's 82.2%
  • 28.2% margin vs SHFS's -262.5%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthLGND logoLGND27.3% revenue growth vs SHFS's -9.2%
ValuePRGO logoPRGOLower P/E (5.5x vs 15.2x)
Quality / MarginsNECB logoNECB28.2% margin vs SHFS's -262.5%
Stability / SafetyBFIN logoBFINBeta 0.56 vs SHFS's 1.83
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs NECB's 4.0%, (2 stocks pay no dividend)
Momentum (1Y)LGND logoLGND+116.0% vs SHFS's -80.2%
Efficiency (ROA)LGND logoLGND3.3% ROA vs SHFS's -389.6%, ROIC -2.3% vs -13.7%

SHFS vs LGND vs BFIN vs PRGO vs NECB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SHFSSHF Holdings, Inc.

Segment breakdown not available.

LGNDLigand Pharmaceuticals Incorporated
FY 2024
Royalty
27.9%$109M
Intangible Royalty Assets
24.4%$95M
Royalty, Kyprolis
9.8%$38M
Material Sales, Captisol, Core
7.9%$31M
Material Sales, Captisol
7.9%$31M
Contract Revenue
7.0%$27M
Service
6.5%$26M
Other (4)
8.5%$33M
BFINBankFinancial Corporation
FY 2024
Deposit Account
68.8%$3M
Bank Servicing
31.2%$2M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
NECBNortheast Community Bancorp, Inc.

Segment breakdown not available.

SHFS vs LGND vs BFIN vs PRGO vs NECB — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLGNDLAGGINGBFIN

Income & Cash Flow (Last 12 Months)

NECB leads this category, winning 3 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 227.0x SHFS's $18M. NECB is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to SHFS's -2.6%. On growth, LGND holds the edge at +122.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
RevenueTrailing 12 months$18M$251M$74M$4.2B$157M
EBITDAEarnings before interest/tax-$11M$52M-$8M$58M$63M
Net IncomeAfter-tax profit-$53M$49M$2M-$1.8B$44M
Free Cash FlowCash after capex-$5M$31M$3M$108M$51M
Gross MarginGross profit ÷ Revenue+104.7%+85.9%+66.2%+34.2%+66.1%
Operating MarginEBIT ÷ Revenue-24.2%+7.0%+6.8%-4.1%+39.6%
Net MarginNet income ÷ Revenue-2.6%+19.3%+5.5%-43.5%+28.2%
FCF MarginFCF ÷ Revenue+2.3%+12.2%+7.4%+2.6%+32.3%
Rev. Growth (YoY)Latest quarter vs prior year+122.8%-7.2%
EPS Growth (YoY)Latest quarter vs prior year-53.8%+15.6%+18.8%-56.4%+6.8%
NECB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SHFS and PRGO each lead in 2 of 6 comparable metrics.

At 7.5x trailing earnings, NECB trades at a 79% valuation discount to BFIN's 36.4x P/E. On an enterprise value basis, NECB's 5.2x EV/EBITDA is more attractive than LGND's 339.3x.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
Market CapShares × price$1M$4.4B$150M$1.6B$338M
Enterprise ValueMkt cap + debt − cash$11M$4.3B$69M$5.1B$332M
Trailing P/EPrice ÷ TTM EPS-0.03x-1006.41x36.36x-1.14x7.53x
Forward P/EPrice ÷ next-FY EPS est.24.64x15.19x5.53x7.81x
PEG RatioP/E ÷ EPS growth rate0.22x
EV / EBITDAEnterprise value multiple339.34x13.36x7.43x5.24x
Price / SalesMarket cap ÷ Revenue0.07x26.04x2.01x0.38x2.15x
Price / BookPrice ÷ Book value/share4.88x0.96x0.55x0.95x
Price / FCFMarket cap ÷ FCF3.11x56.22x27.34x11.17x6.66x
Evenly matched — SHFS and PRGO each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

LGND leads this category, winning 4 of 9 comparable metrics.

NECB delivers a 13.1% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-8 for SHFS. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), BFIN scores 7/9 vs PRGO's 4/9, reflecting strong financial health.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
ROE (TTM)Return on equity-7.6%+5.1%+1.5%-50.7%+13.1%
ROA (TTM)Return on assets-3.9%+3.3%+0.2%-19.8%+2.2%
ROICReturn on invested capital-13.7%-2.3%+1.9%+3.7%+12.5%
ROCEReturn on capital employed-13.1%-2.7%+2.3%+4.3%+16.2%
Piotroski ScoreFundamental quality 0–945745
Debt / EquityFinancial leverage0.01x0.25x1.35x0.21x
Net DebtTotal debt minus cash$10M-$65M-$80M$3.4B-$6M
Cash & Equiv.Liquid assets$2M$72M$119M$532M$81M
Total DebtShort + long-term debt$12M$7M$39M$4.0B$75M
Interest CoverageEBIT ÷ Interest expense-17.46x22.69x0.09x-7.20x1.17x
LGND leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LGND leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in NECB five years ago would be worth $22,109 today (with dividends reinvested), compared to $23 for SHFS. Over the past 12 months, LGND leads with a +116.0% total return vs SHFS's -80.2%. The 3-year compound annual growth rate (CAGR) favors LGND at 41.9% vs SHFS's -64.3% — a key indicator of consistent wealth creation.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
YTD ReturnYear-to-date-55.8%+16.5%0.0%-13.6%+9.2%
1-Year ReturnPast 12 months-80.2%+116.0%+0.2%-52.0%+7.7%
3-Year ReturnCumulative with dividends-95.4%+185.9%+75.6%-58.1%+107.4%
5-Year ReturnCumulative with dividends-99.8%+74.8%+31.6%-60.3%+121.1%
10-Year ReturnCumulative with dividends-99.8%+82.2%+24.6%-77.7%+459.8%
CAGR (3Y)Annualised 3-year return-64.3%+41.9%+20.6%-25.2%+27.5%
LGND leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BFIN and NECB each lead in 1 of 2 comparable metrics.

BFIN is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than SHFS's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NECB currently trades 95.5% from its 52-week high vs SHFS's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
Beta (5Y)Sensitivity to S&P 5001.83x1.03x0.56x1.21x0.81x
52-Week HighHighest price in past year$9.19$247.38$12.96$28.44$25.61
52-Week LowLowest price in past year$0.38$98.89$10.69$9.23$19.27
% of 52W HighCurrent price vs 52-week peak+5.0%+89.5%+92.6%+41.2%+95.5%
RSI (14)Momentum oscillator 0–10027.942.042.353.152.1
Avg Volume (50D)Average daily shares traded275K226K03.3M35K
Evenly matched — BFIN and NECB each lead in 1 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: LGND as "Buy", BFIN as "Hold", PRGO as "Hold", NECB as "Hold". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 20.9% for LGND (target: $268). For income investors, PRGO offers the higher dividend yield at 9.82% vs BFIN's 3.33%.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…BFIN logoBFINBankFinancial Cor…PRGO logoPRGOPerrigo Company p…NECB logoNECBNortheast Communi…
Analyst RatingConsensus buy/hold/sellBuyHoldHoldHold
Price TargetConsensus 12-month target$267.75$36.20
# AnalystsCovering analysts172361
Dividend YieldAnnual dividend ÷ price+3.3%+9.8%+4.0%
Dividend StreakConsecutive years of raises10102
Dividend / ShareAnnual DPS$0.40$1.15$0.98
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.1%0.0%+0.5%
PRGO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

LGND leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). NECB leads in 1 (Income & Cash Flow). 2 tied.

Best OverallLigand Pharmaceuticals Inco… (LGND)Leads 2 of 6 categories
Loading custom metrics...

SHFS vs LGND vs BFIN vs PRGO vs NECB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SHFS or LGND or BFIN or PRGO or NECB a better buy right now?

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -9. 2% for SHF Holdings, Inc. (SHFS). Northeast Community Bancorp, Inc. (NECB) offers the better valuation at 7. 5x trailing P/E (7. 8x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SHFS or LGND or BFIN or PRGO or NECB?

On trailing P/E, Northeast Community Bancorp, Inc.

(NECB) is the cheapest at 7. 5x versus BankFinancial Corporation at 36. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SHFS or LGND or BFIN or PRGO or NECB?

Over the past 5 years, Northeast Community Bancorp, Inc.

(NECB) delivered a total return of +121. 1%, compared to -99. 8% for SHF Holdings, Inc. (SHFS). Over 10 years, the gap is even starker: NECB returned +459. 8% versus SHFS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SHFS or LGND or BFIN or PRGO or NECB?

By beta (market sensitivity over 5 years), BankFinancial Corporation (BFIN) is the lower-risk stock at 0.

56β versus SHF Holdings, Inc. 's 1. 83β — meaning SHFS is approximately 229% more volatile than BFIN relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — SHFS or LGND or BFIN or PRGO or NECB?

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -9. 2% for SHF Holdings, Inc. (SHFS). On earnings-per-share growth, the picture is similar: Northeast Community Bancorp, Inc. grew EPS -7. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SHFS or LGND or BFIN or PRGO or NECB?

Northeast Community Bancorp, Inc.

(NECB) is the more profitable company, earning 28. 2% net margin versus -262. 5% for SHF Holdings, Inc. — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NECB leads at 39. 6% versus -24. 2% for SHFS. At the gross margin level — before operating expenses — SHFS leads at 104. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SHFS or LGND or BFIN or PRGO or NECB more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 24. 6x for Ligand Pharmaceuticals Incorporated — 19. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

08

Which pays a better dividend — SHFS or LGND or BFIN or PRGO or NECB?

In this comparison, PRGO (9.

8% yield), NECB (4. 0% yield), BFIN (3. 3% yield) pay a dividend. SHFS, LGND do not pay a meaningful dividend and should not be held primarily for income.

09

Is SHFS or LGND or BFIN or PRGO or NECB better for a retirement portfolio?

For long-horizon retirement investors, Northeast Community Bancorp, Inc.

(NECB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81), 4. 0% yield, +459. 8% 10Y return). SHF Holdings, Inc. (SHFS) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NECB: +459. 8%, SHFS: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SHFS and LGND and BFIN and PRGO and NECB?

These companies operate in different sectors (SHFS (Financial Services) and LGND (Healthcare) and BFIN (Financial Services) and PRGO (Healthcare) and NECB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SHFS is a small-cap quality compounder stock; LGND is a small-cap high-growth stock; BFIN is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; NECB is a small-cap deep-value stock. BFIN, PRGO, NECB pay a dividend while SHFS, LGND do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SHFS

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
  • Gross Margin > 62%
Run This Screen
Stocks Like

LGND

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 61%
  • Net Margin > 11%
Run This Screen
Stocks Like

BFIN

Income & Dividend Stock

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.3%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

NECB

Dividend Mega-Cap Quality

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 16%
  • Dividend Yield > 1.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SHFS and LGND and BFIN and PRGO and NECB on the metrics below

Revenue Growth>
%
(SHFS: -9.2% · LGND: 122.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.